|Dr. Lishan Aklog M.D.||Chairman & CEO||636.5k||N/A||1966|
|Mr. Dennis M. McGrath CPA||Pres, CFO & Sec.||561.75k||N/A||1957|
|Dr. Brian J. deGuzman M.D.||Chief Medical Officer||414.5k||N/A||1965|
|Mike Havrilla||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Shaun M. O'Neil||Chief Commercial Officer||N/A||N/A||N/A|
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
PAVmed Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.